NCT02815800 (ETHNOPARK) is a NA clinical trial of ETHNODYNE VISIO in Parkinson's Disease, sponsored by University Hospital, Strasbourg, France.

Who is sponsoring NCT02815800?

NCT02815800 is sponsored by University Hospital, Strasbourg, France.

What drugs are being tested in NCT02815800?

Interventions in NCT02815800: ETHNODYNE VISIO.

What condition does NCT02815800 study?

NCT02815800 studies Parkinson's Disease.

Is NCT02815800 still recruiting?

NCT02815800 is currently completed. Last updated 18 April 2018.

Last reviewed 2018-04-18 · How we verify

NCT02815800: ETHNOPARK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Ethnodyne Visio in Parkinson's Disease

Completed NA Last updated 18 April 2018

What this trial tests

NA trial testing ETHNODYNE VISIO in Parkinson's Disease in 24 participants. Completed in 12 March 2018.

Timeline

2 September 2016

Primary endpoint
12 March 2018

12 March 2018

Quick facts

Lead sponsor	University Hospital, Strasbourg, France
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	24
Start date	2 September 2016
Primary completion	12 March 2018
Estimated completion	12 March 2018
Sites	1 location across France

Drugs / interventions tested

ETHNODYNE VISIO

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

University Hospital, Strasbourg, France

Who can join

Adults 40 to 75, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ETHNODYNE VISIO is a food supplement composed of an innovative plant-based active ingredient acting alongside vitamin B2. It is proposed in patients with visual problems. Based on clinical and experimental data, the investigators propose a pilot open study in order to test the efficacy of "Ethnodyne visio" in patients with Parkinson 's disease (PD). The hypothesis is that Ethnodyne visio may improve motor and non motor signs of PD. 24 patients with PD will be evaluated before and after 3 months of add on treatment by Ethnodyne visio.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Plant-Derived Bioactive Compounds in the Management of Neurodegenerative Disorders: Challenges, Future Directions and Molecular Mechanisms Involved in Neuroprotection.
Shoaib S, Ansari MA, Fatease AA, Safhi AY, et al · · 2023 · cited 37× · PMID 36986610 · DOI 10.3390/pharmaceutics15030749

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other University Hospital, Strasbourg, France trials

Trials by the same sponsor.

NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02815800 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
Last refreshed: 18 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02815800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing